Marcello Tucci
A5102738119- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Bone health and treatments
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hormonal and reproductive studies
- Urinary and Genital Oncology Studies
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Bone health and osteoporosis research
- PARP inhibition in cancer therapy
- Renal and related cancers
- Ferroptosis and cancer prognosis
- Economic and Financial Impacts of Cancer
- Salivary Gland Tumors Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Epigenetics and DNA Methylation
- Medical Imaging Techniques and Applications
- Multiple and Secondary Primary Cancers
Azienda Sanitaria Locale di Asti
2019-2025
Collaborative Group (United States)
2023
Start Treatment & Recovery Centers
2023
Ospedale San Luigi Gonzaga
2008-2021
University of Turin
2007-2021
Bayer (Italy)
2017
<h3>Importance</h3> DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some these have been associated sensitivity poly(ADP-ribose) polymerase (PARP) inhibition or platinum-based treatments. However, previous trials assessing treatments CRPC mostly included a biomarker-unselected population; therefore, efficacy is unknown. <h3>Objective</h3> To characterize the antitumor activity therapies men without alterations. <h3>Design,...
Background Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed ligand (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion thus enhancing anti-PD-1/PD-L1 efficacy. Methods This phase I/II study enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung (NSCLC). The objectives I were to investigate the safety tolerability isatuximab (anti-CD38...
The alteration of the bone microenvironment as a consequence skeletal metastases is poorly understood. aim this study was to search for patterns markers in relation primary tumor type, pain, and number sites involved patients with metastases.We studied 323 from various malignancies. We sequentially measured serum concentrations alkaline phosphatase [by an electrophoretic technique (BALP)], carboxy-terminal telopeptide type I collagen (ICTP), calcium (CaS), intact parathyroid hormone (PTH),...
No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 Dec 2001METABOLIC BONE DISEASE INDUCED BY PROSTATE CANCER: RATIONALE FOR THE USE OF BISPHOSPHONATES ALFREDO BERRUTI, LUIGI DOGLIOTTI, MARCELLO TUCCI, ROBERTO TARABUZZI, DARIO FONTANA, and ALBERTO ANGELI BERRUTIALFREDO BERRUTI , DOGLIOTTILUIGI DOGLIOTTI TUCCIMARCELLO TUCCI TARABUZZIROBERTO TARABUZZI FONTANADARIO FONTANA ANGELIALBERTO View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65498-5AboutFull TextPDF ToolsAdd...
We assessed chromogranin A as a tissue biomarker in prostate needle biopsies or plasma biomarker, risk factor for hormone refractory cancer.A total of 211 patients with newly diagnosed cancer treated luteinizing releasing analogues constituted the study cohort. Univariate and multivariate Cox regression analyses were used to assess predictive role expression.Chromogranin expression less than 30% more tumor cells was significantly associated shorter time disease on univariate analysis (HR...
// Michele Iuliani 1 ,* , Francesco Pantano Consuelo Buttigliero 2 Marco Fioramonti Valentina Bertaglia Bruno Vincenzi Alice Zoccoli Giulia Ribelli Marcello Tucci Francesca Vignani Alfredo Berruti 3 Giorgio Vittorio Scagliotti Giuseppe Tonini and Daniele Santini Translational Oncology Laboratory, Medical Oncology, University Campus Bio-Medico of Rome, Italy Department Turin, San Luigi Hospital, Orbassano, U.O. Oncologia Medica, Ospedali Civili di Brescia, * These authors have contributed...
Cabazitaxel is a novel taxane that approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated order to provide early access cabazitaxel docetaxel-pretreated patients and obtain real-world data.We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218...